JP2022552875A5 - - Google Patents

Info

Publication number
JP2022552875A5
JP2022552875A5 JP2022523456A JP2022523456A JP2022552875A5 JP 2022552875 A5 JP2022552875 A5 JP 2022552875A5 JP 2022523456 A JP2022523456 A JP 2022523456A JP 2022523456 A JP2022523456 A JP 2022523456A JP 2022552875 A5 JP2022552875 A5 JP 2022552875A5
Authority
JP
Japan
Prior art keywords
seq
antibody
residues
cancer
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552875A (ja
JP7690468B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056601 external-priority patent/WO2021081052A1/en
Publication of JP2022552875A publication Critical patent/JP2022552875A/ja
Publication of JP2022552875A5 publication Critical patent/JP2022552875A5/ja
Priority to JP2025089701A priority Critical patent/JP2025116128A/ja
Application granted granted Critical
Publication of JP7690468B2 publication Critical patent/JP7690468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523456A 2019-10-22 2020-10-21 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ Active JP7690468B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025089701A JP2025116128A (ja) 2019-10-22 2025-05-29 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924298P 2019-10-22 2019-10-22
US62/924,298 2019-10-22
PCT/US2020/056601 WO2021081052A1 (en) 2019-10-22 2020-10-21 High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025089701A Division JP2025116128A (ja) 2019-10-22 2025-05-29 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ

Publications (3)

Publication Number Publication Date
JP2022552875A JP2022552875A (ja) 2022-12-20
JP2022552875A5 true JP2022552875A5 (enExample) 2023-09-19
JP7690468B2 JP7690468B2 (ja) 2025-06-10

Family

ID=73288710

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523456A Active JP7690468B2 (ja) 2019-10-22 2020-10-21 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ
JP2025089701A Pending JP2025116128A (ja) 2019-10-22 2025-05-29 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025089701A Pending JP2025116128A (ja) 2019-10-22 2025-05-29 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ

Country Status (7)

Country Link
US (1) US12552865B2 (enExample)
EP (1) EP4031250A1 (enExample)
JP (2) JP7690468B2 (enExample)
CN (2) CN119899265A (enExample)
AU (1) AU2020370125A1 (enExample)
CA (1) CA3156761A1 (enExample)
WO (1) WO2021081052A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023274384A1 (zh) * 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向b7h3的抗原结合多肽及其应用
WO2023281445A1 (en) * 2021-07-07 2023-01-12 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Highly specific rabbit single -domain antibodies for drug delivery in immunotherapy applications
JP2024534263A (ja) * 2021-08-27 2024-09-18 セラノティックス カンパニー リミテッド B7-H3及びTGFβに特異的に結合する二重特異性分子、並びにその用途
WO2023173393A1 (zh) * 2022-03-18 2023-09-21 北京天广实生物技术股份有限公司 结合b7-h3的抗体及其用途
JP2025522557A (ja) * 2022-06-23 2025-07-15 フォートビタ バイオロジクス(シンガポール)プライベート リミティド Egfrおよびb7-h3に結合する二重特異性抗体
KR20250059415A (ko) * 2022-08-08 2025-05-02 티크바 알로셀 피티이. 엘티디. B7-h3 항원-결합 분자
KR20250075604A (ko) * 2022-09-22 2025-05-28 상하이 헨리우스 바이오테크, 인크. 항-b7h3 항체 및 사용 방법
WO2024061297A1 (en) * 2022-09-22 2024-03-28 Shanghai Henlius Biotech , Inc. Anti-b7h3 antibodies, multispecific antibodies and methods of use
KR20250099721A (ko) * 2022-11-04 2025-07-02 티-맥시멈 파마슈티컬 (수저우) 컴퍼니 리미티드 B7h3을 표적으로 하는 범용형 car-t 세포 및 이의 제조 방법과 응용
IT202200025596A1 (it) * 2022-12-14 2024-06-14 Ospedale Pediatrico Bambino Gesù Cellule effettrici con recettore chimerico di antigene specifico per B7-H3 (B7-H3 CAR) derivate da IgG per il trattamento di tumori CD276+ e delle malattie autoimmuni
IT202200025593A1 (it) * 2022-12-14 2024-06-14 Ospedale Pediatrico Bambino Gesù Cellule effettrici di recettore chimerico di antigene specifico per B7-H3 (B7-H3 CAR) derivate da IgMper il trattamento di tumori CD276+ e malattie autoimmuni
WO2024140932A1 (en) * 2022-12-29 2024-07-04 Beigene, Ltd. Anti-b7h3 antibodies and methods of use
CN116239691B (zh) * 2022-12-30 2024-04-02 兰州大学第二医院 一种抗b7-h3纳米抗体及其应用
TW202438527A (zh) * 2023-03-17 2024-10-01 瑞士商百濟神州瑞士有限責任公司 抗b7h3抗體以及其使用方法
AU2024295016A1 (en) 2023-07-20 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
CN119371533A (zh) * 2023-07-27 2025-01-28 四川大学 抗b7h3的纳米抗体及其用途
CN117024592B (zh) * 2023-08-24 2024-07-12 四川大学华西医院 抗b7h3抗体及其用途
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
CN120349414A (zh) * 2023-12-28 2025-07-22 博生吉医药科技(苏州)有限公司 抗cd276纳米抗体及其制备方法和应用
WO2025146081A1 (zh) * 2024-01-03 2025-07-10 北京泰德制药股份有限公司 B7-h3结合蛋白
TW202547545A (zh) * 2024-01-26 2025-12-16 美商馬里亞納腫瘤學公司 靶向b7-h3之胜肽及其構築體
CN117736319B (zh) * 2024-02-20 2024-06-04 中国人民解放军军事科学院军事医学研究院 一种针对肉毒毒素的纳米抗体
CN118108850B (zh) * 2024-04-30 2024-07-05 苏州康聚生物科技有限公司 一种纳米抗体
CN118702816B (zh) * 2024-06-03 2025-03-28 内蒙古正德缘生物科技有限责任公司 一种nk细胞及其在抗肿瘤治疗中的应用
WO2026002282A1 (zh) * 2024-06-28 2026-01-02 羿尊生物医药(浙江)有限公司 针对和/或特异性结合b7-h3的纳米抗体
CN119306837B (zh) * 2024-10-15 2025-10-24 普飞(郑州高新技术产业开发区)生物科技有限公司 一种抗cd276的纳米抗体及其应用
WO2026086929A1 (zh) * 2024-10-24 2026-04-30 北京科诺信诚科技有限公司 靶向人b7h3的纳米抗体及其应用
CN119823268A (zh) * 2024-12-26 2025-04-15 广州泛恩生物科技有限公司 一种抗b7h3纳米抗体及其应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP0531434B1 (en) 1990-05-11 1999-07-14 THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
EP0630234B1 (en) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
AU675440B2 (en) 1992-06-18 1997-02-06 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant (pseudomonas) exotoxin with increased activity
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
JP3469580B2 (ja) 1993-10-01 2003-11-25 帝国臓器製薬株式会社 新規なペプチド誘導体
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6296843B1 (en) 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
PT1109812E (pt) 1998-08-27 2005-09-30 Spirogen Ltd Pirrolobenzodiazepinas
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
AU2004204463B2 (en) 2003-01-10 2009-02-12 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
EP1608664B1 (en) 2003-03-31 2009-01-28 Council of Scientific and Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
WO2005051429A2 (en) 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
EP1723152B1 (en) 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazepines
WO2007016150A2 (en) 2005-07-29 2007-02-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Mutated pseudomonas exotoxins with reduced antigenicity
TW200726776A (en) 2005-07-29 2007-07-16 Friedrich Alexander University Of Erlangen Nuremberg CD33-specific single-chain immunotoxin and methods of use
WO2007031741A1 (en) 2005-09-14 2007-03-22 Cambridge Antibody Technology Limited Pseudomonas exotoxin a cd4+ t-cell epitopes
ATE527262T1 (de) 2006-01-25 2011-10-15 Sanofi Sa Neue tomaymycin derivate enhaltende zytotoxische mittel
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20090175784A1 (en) 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
EP2197903B9 (en) 2007-09-04 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
CA2773665C (en) 2009-09-11 2018-02-20 Ira H. Pastan Improved pseudomonas exotoxin a with reduced immunogenicity
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
MX2013012905A (es) 2011-05-06 2014-04-25 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina.
KR20140033391A (ko) 2011-06-09 2014-03-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a
TWI589592B (zh) 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3331909B1 (en) 2015-08-07 2026-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CA3020864A1 (en) * 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
CA3062433A1 (en) 2017-05-15 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
IL277863B2 (en) 2018-04-11 2026-02-01 Inhibrx Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses

Similar Documents

Publication Publication Date Title
EP3368545B1 (en) New polypeptide having affinity to pd-l1
CN114729041A (zh) 用于治疗多种实体瘤的靶向b7h3(cd276)的高亲和力纳米抗体
JP2022514693A5 (enExample)
US10364280B2 (en) Polypeptide
JP2018532383A5 (enExample)
JP2022523710A5 (enExample)
JP2021524242A (ja) 抗−ror1抗体およびその用途
IL273424B2 (en) Novel bispecific cd3/cd19 polypeptide complexes
JP2015526387A5 (enExample)
JP2019535670A5 (enExample)
JP2023508174A5 (enExample)
JP2018512145A5 (enExample)
JP2013535191A5 (enExample)
JP2019512207A5 (enExample)
JP2020515277A5 (enExample)
JP2023543493A5 (enExample)
JP2023508173A5 (enExample)
IL273389B2 (en) Novel anti-cd19 antibodies
JP2024001073A5 (enExample)
US10072093B2 (en) Fusion protein to target and treat acute myeloid leukemia cells
JP2025502247A (ja) ヒトリンパ球抗原6ファミリーメンバーk(ly6k)を標的とする3つの抗体候補の抗体配列
Albrecht et al. Update: Recombinant antibodies: From the laboratory to the clinic
Liu et al. Selection and characterization of single domain antibodies against human CD20
JP7641292B2 (ja) 抗cd19抗体、その使用方法及び製造方法
JP2024539079A5 (enExample)